Tumor rejection antigen P1A is tightly regulated and is restricted to immune privileged organs such as testis and some lineages of cancer cells including myeloma cells. We have studied P1A-specific cytotoxic T lymphocytes (CTL) responses in a mouse plasmacytoma (J558) model. We showed that P1A-specific CTLs could be efficiently activated in vivo and under optimal conditions, P1A-specific CTL cells can completely eliminate established large P1A+ myeloma. Recently we have successfully cloned the human P1A gene from human cancer cells. Preliminary studies suggest that human P1A is preferentially expressed in myeloma cells but not in normal human tissues. Using human-P1A expressing adenovirus to immunize HLA-A2 transgenic mice, we have found that a few A2-binding peptides can stimulate immune splenocytes to produce IFN-gamma, these epitopes can thus be potentially targeted by CTL in human cancer patients.
我公司新研發(fā)的Tumor rejection antigen P1A(腫瘤排斥抗原P1A)抗體已經(jīng)通過檢驗(yàn)測(cè)試已經(jīng)通過檢驗(yàn)測(cè)試，可以應(yīng)用于蛋白印跡（WB），免疫組化（IHC），免疫細(xì)胞化學(xué)（ICC），酶聯(lián)免疫吸附試驗(yàn)（ELISA），免疫沉淀（IP），免疫熒光（IF）實(shí)驗(yàn)。具體信息如下：
編號(hào) 產(chǎn)品名稱
PR-1012， Tumor rejection antigen P1A Antibody
熱忱歡迎國(guó)內(nèi)外科研工作者聯(lián)系訂購(gòu)！
鎮(zhèn)江厚普生物科技有限公司銷售部
2015-10-28